Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition.

Lin VTG, Nabell LM, Spencer SA, Carroll WR, Harada S, Yang ES.

J Natl Compr Canc Netw. 2018 Oct;16(10):1166-1170. doi: 10.6004/jnccn.2018.7056.

2.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
3.

Induction chemotherapy for head and neck cancer: is there still a role?

Ove R, Nabell LM.

Future Oncol. 2016 Jul;12(13):1595-608. doi: 10.2217/fon-2016-0073. Epub 2016 Apr 20. Review.

PMID:
27093876
4.

Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.

Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, Strong TV, Schmalbach CE, Morlandt AB, Agarwal G, Hartman YE, Carroll WR, Richman JS, Clemons LK, Nabell LM, Zinn KR.

Clin Cancer Res. 2015 Aug 15;21(16):3658-66. doi: 10.1158/1078-0432.CCR-14-3284. Epub 2015 Apr 22.

5.

Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies.

Wagner MM, Curé JK, Caudell JJ, Spencer SA, Nabell LM, Carroll WR, Bonner JA.

Radiat Oncol. 2012 Dec 21;7:219. doi: 10.1186/1748-717X-7-219.

6.

By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes.

Vaklavas C, Ross JR, Nabell LM, Forero A, Heslin MJ, Wood TE.

J Natl Compr Canc Netw. 2012 Jan;10(1):7-13.

PMID:
22223865
7.

Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer.

Dragovic AF, Bonner JA, Spencer SA, Nabell LM, Carroll WR, Caudell JJ.

Head Neck. 2011 Nov;33(11):1551-6. doi: 10.1002/hed.21634. Epub 2010 Dec 9.

PMID:
21990218
8.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF.

Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035.

9.

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.

LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD.

Clin Cancer Res. 2010 Mar 15;16(6):1924-37. doi: 10.1158/1078-0432.CCR-09-1883. Epub 2010 Mar 9.

10.

Breast cancer. Clinical practice guidelines in oncology.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel.

J Natl Compr Canc Netw. 2009 Feb;7(2):122-92. Review. No abstract available.

PMID:
19200416
11.

NCCN Task Force Report: breast cancer in the older woman.

Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP.

J Natl Compr Canc Netw. 2008;6 Suppl 4:S1-25; quiz S26-7. Review.

PMID:
18597715
12.

Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.

Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR, Magnuson JS, Spencer SA, Bonner JA.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):410-5. doi: 10.1016/j.ijrobp.2008.04.048. Epub 2008 Jul 16.

PMID:
18635320
13.

Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.

Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, Nabell LM, Meredith RF, Bonner JA.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):676-81. doi: 10.1016/j.ijrobp.2007.10.040. Epub 2008 Mar 20.

PMID:
18355979
14.

Invasive breast cancer.

Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC.

J Natl Compr Canc Netw. 2007 Mar;5(3):246-312. Review. No abstract available.

PMID:
17439758
15.

Genetic/familial high-risk assessment: breast and ovarian.

Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Feb;4(2):156-76. No abstract available.

PMID:
16451772
16.

Breast cancer.

Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 May;3(3):238-89. No abstract available.

PMID:
16002000

Supplemental Content

Loading ...
Support Center